Business Context and Reporting Period
This Form 8-K filing by Alphatec Holdings, Inc. (Alphatec) reports material events occurring on March 6, 2018, and consummated on March 8, 2018. The filing details a private placement of equity, the acquisition of SafeOp Surgical, Inc., a warrant exercise, amendments to credit facilities, and executive management changes.
Key Financial Metrics and Capital Transactions
- Private Placement Proceeds: Approximately $39.7 million received at the first closing, with an additional $5.5 million expected at the second closing. Total gross proceeds are approximately $45.2 million.
- Securities Issued (Private Placement): 39,746 shares of Series B Convertible Preferred Stock (convertible to ~12.6 million common shares) and warrants to purchase up to 10.7 million common shares at $3.50 per share.
- Acquisition Consideration (SafeOp Surgical): $15 million in cash, 3.27 million shares of common stock, $3 million in convertible notes (convertible to ~932,000 shares), and warrants to purchase 2.2 million shares at $3.50 per share. Additional 1.33 million shares are issuable upon milestone achievement.
- Warrant Exercise Proceeds: $3.4 million received from the exercise of 1.7 million shares of an existing warrant. Up to $1.4 million in additional proceeds are expected from remaining shares.
- Debt and Liquidity: The company amended credit agreements with MidCap Funding IV Trust and Globus Medical, Inc. to extend maturity dates (MidCap to Dec 31, 2022) and establish a minimum liquidity covenant of $5.0 million through March 31, 2019.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or margins) for the period. However, it reports significant structural changes:
- Capital Structure: Significant dilution potential via the issuance of convertible preferred stock, new warrants, and merger consideration.
- Management: Patrick S. Miles transitioned from Executive Chairman to Chairman and CEO; Terry Rich transitioned from CEO to President and COO.
- Board Composition: The board size increased to twelve members with the appointment of three new directors (James L.L. Tullis, Jason Hochberg, and Evan Bakst).
- Operations: Completion of the merger with SafeOp Surgical, Inc., making it a wholly-owned subsidiary.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds from the private placement and warrant exercise will be used for general corporate purposes, working capital, and funding strategic initiatives, including a portion of the SafeOp merger consideration.
- Stockholder Approval: Conversion of Series B Preferred Stock and exercise of certain warrants are contingent upon stockholder approval required by NASDAQ rules due to the issuance exceeding 19.99% of outstanding shares.
- Anti-Dilution Protection: The Series B Preferred Stock includes a full ratchet anti-dilution provision for one year following the effective date of the resale registration statement.
- Risks: The filing includes standard forward-looking statement disclaimers regarding the integration of SafeOp, market conditions, and the ability to meet financial covenants.
Investor Verification Checklist
- Verify the status of the required stockholder approval for the conversion of Series B Preferred Stock and issuance of merger-related shares.
- Confirm the final closing of the second tranche of the private placement and the total aggregate proceeds received.
- Review the full text of the Merger Agreement and Purchase Agreement (Exhibits 2.1 and 10.1) for specific representations, warranties, and indemnification caps.
- Monitor the company's ability to maintain the $5.0 million minimum liquidity covenant established in the amended Globus Facility Agreement.
- Assess the impact of the new board appointments and executive role changes on strategic direction.